ArticleAngiogenesis2012
A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors.
Article in Angiogenesis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?Frontiers in immunology · 2024Review
- Comparison of a NewCells · 2021Article
- Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.International journal of molecular sciences · 2021Review
- Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas .Vaccines · 2020Article
- Angiomotin-p130 inhibits β-catenin stability by competing with Axin for binding to tankyrase in breast cancer.Cell death & disease · 2019Article
- The physiological role of Motin family and its dysregulation in tumorigenesis.Journal of translational medicine · 2018Review
- Early prediction of revascularisation by angiomotin-targeting positron emission tomography.Theranostics · 2018Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- CSPG4: a prototype oncoantigen for translational immunotherapy studies.Journal of translational medicine · 2017Review
- Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.Oncotarget · 2016Article
- Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells.OncoTargets and therapy · 2016Article
- Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Journal of translational medicine · 2015Review
- Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.Oncogene · 2015Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Oncoimmunology · 2015Article
- The Angiomotins--from discovery to function.FEBS letters · 2014Review
- Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth.Oncoimmunology · 2014Article
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.BioMed research international · 2014Review
- Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiomotin (Amot) is one of several identified angiostatin receptors expressed by the endothelia of angiogenic tissues. We have shown that a DNA vaccine targeting Amot overcome immune tolerance and induce an antibody response that hampers the progression of incipient tumors. Following our observation of increased Amot expression on tumor endothelia concomitant with the progression from pre-neoplastic lesions to full-fledged carcinoma, we evaluated the effect of anti-Amot vaccination on clinically evident tumors. Electroporation of plasmid coding for the human Amot (pAmot) significantly delayed the progression both of autochthonous tumors in cancer prone BALB-neuT and PyMT genetically engineered mice and transplantable TUBO tumor in wild-type BALB/c mice. The intensity of the inhibition directly correlated with the titer of anti-Amot antibodies induced by the vaccine. Tumor inhibition was associated with an increase of vessels diameter with the formation of lacunar spaces, increase in vessel permeability, massive tumor perivascular necrosis and an effective epitope spreading that induces an immune response against other tumor associated antigens. Greater tumor vessel permeability also markedly enhances the antitumor effect of doxorubicin. These data provide a rationale for the development of novel anticancer treatments based on anti-Amot vaccination in conjunction with chemotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.